News

This AAD 2025 interview with Bhutani covers some of the takeaways from her presentation on use of JAK inhibitors for alopecia areata among pregnant or breastfeeding women.

Psychosocial interventions reduced depressive symptoms in CKD but did not have a significant impact on patients’ quality of life.

In this interview at AAD 2025, Bhutani highlights several points of consideration for clinicians treating patients who are pregnant and suffering from alopecia areata.

This interview with Melinda Gooderham, MD, covers recent findings from the phase 3 ARRECTOR trial on roflumilast foam 0.3% in scalp and body psoriasis.

This interview at the Skin of Color Society (SOCS) Scientific Symposium features Elbuluk describing her plans as newly-elected president of SOCS.

An analysis of data from the DELTA program at AAD 2025 sheds light on the efficacy of delgocitinib for chronic hand eczema.

Crystal Aguh, MD, discusses a study from AAD 2025 examining HbA1c levels and outcomes in CCCA.

This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.

Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.

New data from AAD 2025 and topline results from the ICONIC program underline the potential of icotrokinra in moderate to severe plaque psoriasis.

Robert Bissonnette, MD, discusses data from the ICONIC-LEAD trial and the potential role of icotrokinra in plaque psoriasis.

In this interview at AAD 2025, Craiglow speaks on her team’s late-breaking findings on baricitinib among adolescents with severe alopecia areata.

LIBERTY-BP ADEPT provides further insight into the potential of dupilumab in bullous pemphigoid ahead of the June 2025 PDUFA date.

Data from AAD 2025 examine the effect of GLP-1 RAs on HS among patients with overweight or obesity.

Phase 3 data from ruxolitinib cream 1.5% presented at AAD 2025 demonstrate the potential of the topical agent in prurigo nodularis.

This interview covers the findings presented at AAD 2025 from the SIGNAL-AA study on bempikibart for alopecia areata.

Stein Gold highlights her team's findings on tapinarof cream (Vtama) 1% from the 48-week ADORING 3 extension for those aged 2 to 17 with atopic dermatitis.

David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

Susan Taylor, MD, discusses a study examining the effect of GLP-1 RA use relative to nonuse in central centrifugal cicatricial alopecia at AAD 2025.

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

This AAD 2025 interview features a discussion with Sonja Ständer, MD, new phase 3 findings from OLYMPIA 1 and 2 on nemolizumab in patients with prurigo nodularis.

New 3-year data from ADjoin demonstrate the efficacy and safety profile of lebrikizumab in moderate to severe atopic dermatitis.

In this segment of Silverberg’s interview, she highlights providing anticipatory guidance for parents of children with molluscum as well as treatment options.

HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.

In addition to being less likely to become pregnant, women with alcohol-associated hepatitis faced a greater risk of adverse pregnancy outcomes.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

This February 2025 month in review covers key pulmonology updates, including FDA reviews for brensocatib and PRGN-2012, dupilumab’s COPD data, and wildfire air quality risks.